Navigation Links
HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
Date:9/12/2011

ard-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.CONTACTS:

Jerome Lyons

Tamara A. SeymourOffice Manager

Chief Financial OfficerT: 206.826.9900

T: 858.356.5582jlyons@hemaquest.com

tseymour@hemaquest.com
'/>"/>

SOURCE HemaQuest Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
2. HemaQuest Pharmaceuticals, Inc. Presents Promising Clinical Results at 52nd Annual Meeting of the American Society of Hematology (ASH)
3. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
4. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
5. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
6. AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
7. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
8. Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
9. Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
10. Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
11. Oramed Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
(Date:10/30/2014)... 2014  TWi Pharmaceuticals, Inc. today announced that it ... and Drug Administration (FDA) on its Abbreviated New Drug ... the generic equivalent to Eisai Inc.,s Aricept® 23mg.  Aricept® ... TWi Pharmaceuticals is preparing to launch the product ... Pharmaceuticals USA , at the earliest ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... CITY, Md., Oct. 11, 2011 Christine K. Pierre, ... a "Professional Woman of the Year" by the National ... recognizes Pierre,s "outstanding leadership and commitment" within her profession, ... women. Pierre founded RxTrials, Inc., in 1994, ...
... Johnson (NYSE: JNJ ) will host a conference ... Tuesday, October 18, 2011, to review third-quarter results.  Dominic Caruso, ... Vice President, Investor Relations, will host the call. ... visiting the Company,s website at www.investor.jnj.com . ...
Cached Medicine Technology:Christine Pierre Selected as "Professional Woman of the Year" 2
(Date:10/30/2014)... 30, 2014 Victory Healthcare, a ... 2014 third quarter infection rates and patient satisfaction ... rates of only two percent or less, and ... exceeding 98 percent. , “We are delighted with ... rising satisfaction scores,” said Robert Helms, chairman and ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Scientists who used ... laboratory say their breakthrough could provide a new way ... stomach diseases. The team used human pluripotent stem ... in the body -- to grow the functional miniature ... bacteria, a major cause of ulcers and stomach cancer. ...
(Date:10/30/2014)... Many U.S. colleges have indoor tanning salons on ... risk for skin cancer, researchers report. Tanning ... so colleges should adopt tanning-free policies, to help ... health efforts are needed to raise university administration ... indoor tanning poses to young adults in order ...
(Date:10/30/2014)... (HealthDay News) -- A new vaccine that could help ... approved by the U.S. Food and Drug Administration on ... the ages of 10 and 25 from invasive meningococcal ... bacteria. The bacteria can infect the bloodstream (sepsis) ... brain. It is a leading cause of bacterial meningitis, ...
(Date:10/29/2014)... The development of minimally and even non-invasive technologies is ... for instance, to carry out a range of operative ... scalpel, leaving only tiny scars as a result. Similar ... active agents to patients – instead of using injections ... be possible to supply them via a plaster which ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... during and after treatment resulted in less fatigue, greater ... - Exercise during and after treatment improves quality of ... or prostate cancer, a new study finds. , "Using ... potential to benefit patients both physically and psychologically, as ...
... ... 7,000 stores in under five months of operation. The site offers 30,000 coupons from 7,000 ... 500 votes per day, making it one of the fastest growing coupons/deals sites ever. ... (PRWEB) May 27, 2010 ...
... , THURSDAY, May 27 (HealthDay News) -- A new ... that many people don,t know enough about sun damage ... survey showed that despite our repeated warnings about the ... sun protection, many people could not correctly answer true/false ...
... ... and published by Random House Mondadori this ,practical guide teaches Latina women how to ... ... Guía Para Vestir Mejor (Discover Your Style: Your Guide to Dressing Better) written ...
... "color-coded" laboratory mice are providing researchers with a novel ... monitor the cellular immune responses of transplanted tissue in ... the June issue of Nature Medicine , which ... a key consideration in developing strategies to improve transplant ...
... at the UCLA Medical Center found that antiviral therapy ... is the most cost-effective approach to treating patients with ... Full details appear in the June issue of ... behalf of the American Association for the Study of ...
Cached Medicine News:Health News:Exercise Boosts Health of Cancer Patients 2Health News:Coupon Site TrimBack.com Adds 7000th Online Store 2Health News:Many People Still Don't Know How to Protect Against Skin Cancer 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 3Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 2Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 3Health News:Antiviral therapy during compensated cirrhosis most cost-effective approach 2
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
Medicine Products: